23 Jan Xintela
Lucienne VonK, Ph.D., Chief Scientific Officer
April 16 | 2:15pm | Salone dei Cavalieri, Section 2
Lund, Sweden
(NASDAQ: XINT)
Xintela is a clinical-stage biopharma company developing novel allogeneic stem cell therapies based on its proprietary stem cell marker technology. Xintelas product platform XSTEM® consists of homogenous integrin α10β1-selected Mesenchymal stem cells (MSCs) from adipose tissue, with superior potency and consistency. In a Phase I/IIa study on knee osteoarthritis (OA) patients, safety has been demonstrated with three different dose levels in 24 patients and patients report reduced pain and improved function of the knee joint. An interim analysis of safety and efficacy, 18 months after dosing, will be performed in Q1 2025. XSTEM is also investigated in a Phase I/IIa clinical study for the treatment of difficult-to-heal venous leg ulcers (VLU). Extensive preclinical studies in large animals, support disease modifying effects in OA and VLU.
